India, April 24 -- Vistin Pharma ASA (VISTN), a pharmaceutical manufacturing company, announced on Friday financial results for the first quarter of 2026.
Vistin produces an estimated 10% of the world's metformin hydrochloride, an essential medication in the treatment and management of type-2 diabetes.
Q1 Financial Report
The company reported a first quarter revenue of 112.20 million Norwegian kroner (MNOK), showing a slight dip from Q1 revenue of MNOK 115 in 2025.
The earnings for Q1 before interest, taxes, depreciation and amortization (EBITDA) were MNOK 27.32, compared with MNOK 30.21 in the same period the prior year.
Vistin recorded net profits of MNOK 21.49 in Q1 2026, while in Q1 2025, profits were comparable at MNOK 21.69.
The...